Peptide Dosage Guide: Evidence-Based Protocols

Peptide dosing is not a one-size-fits-all calculation. Each compound interacts with distinct receptor systems and biological pathways, meaning the therapeutic window, the range between an effective dose and one that produces diminishing returns or side effects, varies significantly from peptide to peptide. Factors that influence optimal dosing include body weight, body composition, age, metabolic rate, organ function (particularly liver and kidney clearance), concurrent medications, the specific condition being addressed, and individual receptor sensitivity. Unlike small-molecule pharmaceuticals where standardized dosing is established through large Phase III clinical trials, most research peptides have dosing ranges derived from preclinical studies, smaller clinical investigations, and accumulated clinical experience from your specialists. This makes specialist oversight not merely advisable but essential: a prescribing doctor would select a starting dose based on individual health profile, monitor your response through clinical assessment and blood work, and adjust the protocol accordingly. Three core principles govern responsible peptide dosing. First, start conservatively. Beginning at the lower end of a dosing range allows A specialist to assess tolerance and response before escalating. Second, titrate based on response. Dose adjustments should be guided by objective markers (blood work, body composition measurements, clinical assessments) rather than subjective perception alone. Third, respect cycle protocols. Most peptides require defined on-off cycling to prevent receptor desensitization, maintain physiological balance, and allow A specialist to evaluate sustained effects versus acute responses.

Recovery peptides target tissue repair mechanisms through distinct molecular pathways, and their dosing protocols reflect these different mechanisms of action. BPC-157 is dosed at 250-500mcg per day, administered via subcutaneous injection near the injury site or abdominally for systemic effects. Standard cycle length is 4-6 weeks, with a 2-4 week rest period between cycles. Many protocols incorporate a loading phase of 500mcg daily for the first 1-2 weeks before reducing to 250mcg for maintenance. BPC-157 is supplied as a 5mg lyophilized vial; reconstituting with 2mL bacteriostatic water yields a concentration of 2500mcg/mL, meaning a 250mcg dose equals 0.1mL (10 units on an insulin syringe). Individuals taking anticoagulants or blood pressure medications require adjusted protocols due to BPC-157's effects on the vascular system and nitric oxide signaling. TB-500 (Thymosin Beta-4) follows a loading-and-maintenance protocol: 2-2.5mg administered subcutaneously twice weekly during the loading phase (4-6 weeks), reducing to 2mg once weekly for maintenance (2-4 weeks). TB-500 is supplied as a 5mg vial; reconstituting with 2mL bacteriostatic water yields 2500mcg/mL. The loading phase is critical for achieving tissue saturation, as TB-500 works by upregulating actin expression and facilitating cell migration into damaged areas. BPC-157 and TB-500 are frequently combined in recovery protocols because they operate through complementary mechanisms: BPC-157 promotes angiogenesis via VEGFR2 while TB-500 facilitates cellular migration via actin regulation. GHK-Cu (copper peptide) is dosed at 1-2mg daily via subcutaneous injection for systemic use, with cycles lasting 4-8 weeks. GHK-Cu is also available for topical application in dermatological protocols, where it can be used on an ongoing basis. The copper component gives reconstituted solutions a characteristic blue-green tint, which is normal and indicates proper compound identity. GHK-Cu's dual systemic and topical applications make it unique among recovery peptides, and A specialist will determine the appropriate route based on whether the treatment target is localized skin tissue or systemic collagen and tissue remodeling.

Growth hormone-modulating peptides require particularly careful dosing because they interact with the hypothalamic-pituitary axis, a master regulatory system that influences metabolism, body composition, sleep architecture, and tissue maintenance. CJC-1295/Ipamorelin is administered as a combined protocol: 100mcg CJC-1295 plus 100mcg Ipamorelin, injected together subcutaneously twice daily (morning and before bed). Cycles run 8-12 weeks followed by a 4-8 week rest period to prevent pituitary desensitization. Evening doses are timed 30-60 minutes before sleep to coincide with the natural nocturnal growth hormone pulse, amplifying rather than replacing the body's endogenous rhythm. Each peptide is reconstituted separately: 5mg with 2.5mL bacteriostatic water yields 2000mcg/mL for each. Baseline blood work including IGF-1, fasting glucose, HbA1c, and thyroid panel is required before initiating this protocol, and A specialist will monitor these markers throughout the cycle. Tesamorelin is the only FDA-approved peptide in this category (approved for HIV-associated lipodystrophy). The standard research protocol is 1-2mg administered subcutaneously once daily, typically before bedtime on an empty stomach. Cycles last 8-12 weeks. Tesamorelin specifically stimulates growth hormone releasing hormone (GHRH) receptors and has demonstrated significant visceral fat reduction in clinical trials. Because it directly modulates the GH axis, monitoring of IGF-1 levels, glucose metabolism, and body composition through DEXA scanning is standard practice during tesamorelin protocols. Sermorelin is a 29-amino acid GHRH analogue dosed at 200-300mcg administered subcutaneously once daily, typically before bedtime on an empty stomach. Cycles run 8-12 weeks with 4-week rest periods. Sermorelin stimulates the pituitary to release growth hormone through the natural GHRH pathway, producing a more physiological GH pulse pattern compared to exogenous GH. Its shorter half-life (10-20 minutes) compared to CJC-1295 results in a brief, defined GH pulse rather than sustained elevation. Sermorelin is supplied as a 2mg or 5mg lyophilized vial. As with other GH peptides, baseline IGF-1, glucose, and thyroid panels are required before initiation. Sermorelin is commonly used as a gentler entry point to GH peptide protocols due to its established safety profile and natural pulsatile stimulation pattern.

Cognitive peptides are administered intranasally, a route that provides relatively direct access to the central nervous system by bypassing the blood-brain barrier through olfactory and trigeminal nerve pathways. This administration route requires specific dosing considerations. Semax is dosed at 200-600mcg per day, divided into 1-3 intranasal administrations. Standard protocols run 10-20 days followed by an equal rest period. Some protocols use 14 days on, 14 days off cycling. Effects on cognitive performance, focus, and mental clarity are often noted within the first 2-3 days of administration. Semax has been approved as a prescription medication in Russia since 2001, providing decades of clinical safety data. Individuals taking psychiatric medications, particularly SSRIs, MAOIs, or dopaminergic agents, require careful dose calibration to avoid neurotransmitter interactions, as Semax upregulates BDNF expression and modulates dopaminergic and serotonergic pathways. Selank is dosed at 250-500mcg per day, administered intranasally in 2-3 divided doses. Cycle length is 14-21 days with a rest period of equal length. Selank is a synthetic analogue of the endogenous immunomodulatory peptide tuftsin, and it modulates GABAergic neurotransmission, producing anxiolytic effects without the sedation or dependence associated with benzodiazepines. Like Semax, Selank is approved in Russia, where it has been used clinically for generalized anxiety disorder. A specialist would assess whether Selank or Semax (or a sequential protocol) is more appropriate based on your primary cognitive goals: Semax for focus, learning, and neuroprotection; Selank for anxiety reduction and emotional regulation.

Metabolic peptides target fat metabolism and energy regulation pathways, and their protocols tend to be longer than other peptide categories because metabolic changes are inherently gradual. AOD-9604 is dosed at 300mcg administered subcutaneously once daily, ideally in the morning on an empty stomach. Protocols are typically 12-20 weeks, significantly longer than most peptide cycles, reflecting the gradual nature of fat metabolism changes. Morning fasted administration optimizes the compound's fat-burning activity. AOD-9604 is a modified fragment (amino acids 177-191) of human growth hormone, retaining the lipolytic (fat-burning) properties without the growth-promoting or diabetogenic effects of full-length GH. Reconstituting a 5mg vial with 1.67mL bacteriostatic water yields 3000mcg/mL, meaning a 300mcg dose equals 0.1mL. Baseline body composition measurements (DEXA scan or similar), metabolic panel, and thyroid function tests should be completed before starting, with follow-up assessments at 6-8 week intervals. MOTS-c is a mitochondrial-derived peptide dosed at 5-10mg administered subcutaneously 3 times weekly. Cycles run 4-8 weeks. MOTS-c activates the AMPK pathway, often called the cell's master energy regulator, enhancing glucose uptake independent of insulin signaling and promoting fatty acid oxidation in skeletal muscle. This mechanism makes MOTS-c particularly interesting for metabolic health optimization. Exercise prior to or following injection may enhance MOTS-c's metabolic effects by creating an additive AMPK activation signal. Cagrilintide is a long-acting amylin analogue dosed at 0.3-4.5mg administered subcutaneously once weekly. As an investigational compound currently in Phase III clinical trials, dosing protocols are derived from published trial data rather than established clinical practice. Cagrilintide works through the amylin receptor pathway, which is distinct from GLP-1 signaling, reducing appetite via brainstem satiety centers and slowing gastric emptying. Its extended half-life (approximately one week due to fatty acid acylation) enables convenient weekly dosing. Gastrointestinal effects, particularly transient nausea, are the most commonly reported side effects in clinical trials. Monitoring should include body weight, metabolic panels, fasting glucose, and HbA1c. Because cagrilintide is still under active clinical investigation, protocols should be guided by A specialist with current knowledge of the evolving trial data.

These peptides serve highly specific biological functions and have correspondingly unique dosing protocols. PT-141 (Bremelanotide) is FDA-approved for hypoactive sexual desire disorder (HSDD) in premenopausal women. It is dosed at 1-2mg administered subcutaneously approximately 45 minutes before anticipated sexual activity. PT-141 should not be used more than once every 24 hours and no more than 8 doses per month. Unlike phosphodiesterase inhibitors that act on vascular mechanisms, PT-141 works centrally through melanocortin-4 receptors in the hypothalamus, modulating sexual desire at the neurological level. Common side effects include transient nausea and flushing, which typically diminish with subsequent administrations. A specialist would start at the lower dose and adjust based on response and tolerance. DSIP (Delta Sleep Inducing Peptide) is dosed at 100-300mcg administered subcutaneously 30-60 minutes before bedtime. DSIP uses short cycling: 5-10 days on followed by 5 days off. Effects often improve during the off-cycle as regulatory changes consolidate. DSIP promotes delta-wave sleep, the deepest restorative phase, without causing next-day grogginess or dependence. A specialist would assess the underlying causes of sleep dysfunction before initiating DSIP, as conditions like sleep apnea and restless leg syndrome require different interventions. Epithalon (Epitalon) targets cellular aging through telomerase activation. The dosing protocol is 5-10mg administered subcutaneously once daily for short intensive cycles of 10-20 days, repeated approximately 2 times per year (every 6 months). This cycling pattern allows for telomerase activation and telomere elongation during treatment periods with extended rest between cycles. Reconstituting a 10mg vial with 2mL yields 5000mcg/mL. Telomerase activation is a powerful biological process, and A specialist may order baseline telomere length testing to establish a reference point for tracking the effects of Epithalon protocols over time.

The majority of research peptides (12 of 14 compounds) are administered via subcutaneous injection, delivering the peptide into the fatty tissue layer beneath the skin for gradual systemic absorption. The standard injection sites are the lower abdomen (2 inches from the navel), the front of the thigh, and the outer upper arm. Rotate injection sites to prevent localized tissue irritation or lipodystrophy. Insulin syringes (1mL/100-unit with 29-31 gauge needles) are the standard delivery device. The fine gauge minimizes discomfort and tissue damage. Always use a new, sterile syringe for each injection and never share needles or syringes. Two compounds, Semax and Selank, are administered intranasally. This route delivers cognitive peptides efficiently to brain targets through olfactory nerve pathways. Intranasal administration requires specific nasal spray devices and technique: clear nasal passages before administration, tilt the head slightly forward, insert the spray tip into one nostril while occluding the other, and inhale gently during spray delivery. Alternate nostrils between doses. GHK-Cu uniquely supports both subcutaneous injection for systemic effects and topical application for skin-targeted protocols. Topical GHK-Cu is applied directly to target skin areas and does not require injection. All injectable peptides require reconstitution from lyophilized powder before use. Refer to the reconstitution guide for detailed preparation instructions, and always follow A specialist's specific directions for the protocol.

A well-designed peptide protocol is more than a dosage number; it is a comprehensive treatment plan tailored to individual biology. A your specialist will consider multiple factors when designing the protocol. Baseline assessment forms the foundation. Before initiating any peptide protocol, comprehensive blood work establishes your starting point: hormone panels (IGF-1, testosterone, thyroid), metabolic markers (fasting glucose, HbA1c, insulin, lipid panel), organ function (liver enzymes, kidney function via creatinine and eGFR), and compound-specific markers. For growth hormone peptides, IGF-1 and glucose metabolism are critical. For recovery peptides, inflammatory markers (CRP, ESR) and imaging of the injury site provide baseline references. Protocol stacking, using multiple peptides simultaneously, requires particular specialist expertise. Common evidence-based combinations include BPC-157 plus TB-500 for comprehensive tissue repair, CJC-1295/Ipamorelin plus Tesamorelin for GH axis optimization, and Semax sequenced with Selank for combined cognitive and anxiolytic benefits. However, stacking increases complexity: more potential interactions, more variables to monitor, and greater demand for careful dose calibration. A specialist would determine whether a single-compound or multi-compound approach is appropriate. Timing considerations affect efficacy. Growth hormone peptides are optimally administered before sleep to amplify natural nocturnal GH pulses. AOD-9604 is best taken fasted in the morning for maximal lipolytic activity. DSIP is taken 30-60 minutes before bedtime. PT-141 is taken 45 minutes before anticipated activity. A specialist would provide a precise timing schedule integrated with your daily routine.

Ongoing monitoring is the safety backbone of any peptide protocol. A specialist would establish a monitoring schedule that typically includes blood work at 4-8 week intervals during active protocols, with specific panels determined by the compound category being used. For growth hormone peptides (CJC-1295/Ipamorelin, Tesamorelin), monitoring focuses on IGF-1 levels (to ensure they remain within therapeutic range without excessive elevation), fasting glucose and HbA1c (GH can influence insulin sensitivity), and body composition measurements. For recovery peptides (BPC-157, TB-500, GHK-Cu), monitoring includes inflammatory markers, imaging of injury sites where applicable, and functional assessments of the healing tissue. For cognitive peptides (Semax, Selank), clinical assessment of cognitive function, mood, and anxiety levels guides protocol adjustments. For metabolic peptides (AOD-9604, MOTS-c), metabolic panels, body composition scans, and exercise performance metrics provide objective data. Dose adjustments are made based on objective data, not assumptions. If blood markers indicate insufficient response, A specialist may increase the dose within the established range. If markers suggest excessive stimulation (elevated IGF-1, glucose changes, unexpected side effects), the dose may be reduced or the protocol paused. This iterative, data-driven approach is why self-dosing without specialist oversight is strongly discouraged. Side effects should be reported to A specialist promptly. Common injection-site reactions (mild redness, temporary soreness) are typically benign. Systemic effects such as water retention, joint stiffness (with GH peptides), nausea (with PT-141), or unusual fatigue warrant medical evaluation and potential protocol adjustment. Proper storage of reconstituted peptides is also critical to maintaining accurate dosing. A degraded peptide delivers an unpredictable dose regardless of how precisely you measure. Refer to the peptide storage guide for detailed storage requirements, especially important in Thailand's tropical climate.